NBIX - ニュ―ロクライン・バイオサイエンシズ （Neurocrine Biosciences Inc.） ニュ―ロクライン・バイオサイエンシズNBIXのチャート
NBIXの企業情報
| symbol | NBIx |
|---|---|
| 会社名 | Neurocrine Biosciences Inc. （ニュ―ロクライン・バイオサイエンシズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: Biological Products (No Diagnostic Substances) |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 ニューロクライン・バイオサイエンシス（Neurocrine Biosciences Inc）は神経と内分泌関連疾患及び障害の治療薬の発見・開発・商業化に従事する企業。同社の薬品候補は子宮内膜症、ストレス関連疾患、疼痛、糖尿病、不眠症、及び他の神経と内分泌関連疾患及び障害などの製薬市場に提供する。同社は各自の研究・開発段階にある11のプログラムを持ち、そのうち、6つのプログラムは臨床開発段階にある。同社は６つのプログラムのためのコラボレーションを締結した。同社の主要な臨床開発プログラム「elagolix」は子宮内膜症治療用の薬剤候補。同社の製品ポートフォリオは「Elagolix」、小胞モノアミントランスポーター２阻害剤（VMAT2）、コルチコトロピン遊離因子タイプ２（CRF2）ペプチド・アゴニストウロコルチン、コルチコトロピン遊離因子タイプ１（CRF1）拮抗薬（561679）、コルチコトロピン遊離因子タイプ１（CRF1）拮抗薬（586529）、Gタンパク質共役型受容体119（GPR119）、VMAT2、性腺刺激ホルモン放出ホルモン（GnRH）拮抗薬、抗てんかん薬、Gタンパク質共役受容体と「Indiplon」などを含む。 ニュ―ロクライン・バイオサイエンシズは米国のバイオ医薬品メ―カ―。主に、神経及び内分泌関連疾患や障害である、子宮内膜症、糖尿病、睡眠障害、疼痛、ストレス性障害、てんかんなどの治療薬の臨床・開発に従事する。カリフォルニア州サンディエゴに拠点を置き、世界的に事業を展開。 neurocrine biosciences, inc of san diego is a product based biopharmaceutical company focusing on the development and commercialization of innovative pharmaceutical products to treat unmet medical needs. the company's research and development efforts are focused on neurological and endocrine diseases and disorders. our product candidates address some of the largest pharmaceutical markets in the world including endometriosis, irritable bowel syndrome, anxiety, depression, pain, diabetes, insomnia, and other neurological and endocrine related diseases and disorders |
| 本社所在地 | 12780 El Camino Real San Diego CA 92130 USA |
| 代表者氏名 | William H. Rastetter ウィリアムH.ラスターセッター |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 858-617-7600 |
| 設立年月日 | 33604 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 1996年 |
| 従業員数 | 400人 |
| url | www.neurocrine.com |
| nasdaq_url | https://www.nasdaq.com/symbol/nbix |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -30.46900 |
| 終値（lastsale） | 112.3 |
| 時価総額（marketcap） | 10159709240.3 |
| 時価総額 | 時価総額（百万ドル） 9776.119 |
| 売上高 | 売上高（百万ドル） 323.28200 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 9646.264 |
| 当期純利益 | 当期純利益（百万ドル） -51.96200 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Neurocrine Biosciences Inc. revenues increased from $6.3M to $168M. Net loss decreased 65% to $47.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Investment income net increase from $1.9M to $6.3M (income). Basic Earnings per Share excluding Extraordinary Items increased from -$1.58 to -$0.53. |
NBIXのテクニカル分析
NBIXのニュース
Mercer Global Advisors Inc. ADV Purchases 259 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) 2023/05/24 09:28:43 The AM Reporter
Mercer Global Advisors Inc. ADV lifted its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) by 9.2% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 3,086 shares of the company’s stock after buying an additional 259 shares during the quarter. Mercer Global Advisors Inc. ADV’s holdings in Neurocrine Biosciences were worth $369,000 […]
Neurocrine Biosciences: In Limbo Until The Arrival Of The ''Next Big Thing'' Beyond Ingrezza 2023/05/24 08:31:45 Seeking Alpha
Neurocrine Biosciences shows promising growth, boosted by Ingrezza sales, but struggles with high operational costs. Find out why NBIX stock is a Hold.
Neurocrine sees August FDA action date for valbenazine for chorea 2023/05/19 15:46:36 Seeking Alpha
Neurocrine Biosciences (NBIX) noted that its supplemental New Drug Application for valbenazine as a treatmetn for chorea associated with Huntington''s disease has an Aug
Neurocrine Biosciences Announces Publication of Full KINECT-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington''s Disease in The Lancet Neurology 2023/05/19 12:30:00 PR Newswire
- Statistically Significant Improvement in Chorea Associated with Huntington''s Disease Seen as Early as Week 2 - Chorea Improvement Supported by Statistically Significant Clinical Global Impression of Change (CGI-C) Response Status and Patient Global Impression of Change (PGI-C) Response…
Neurocrine Biosciences Announces Publication of Full KINECT™-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington''s Disease in The Lancet Neurology 2023/05/19 12:30:00 Neurocrine Biosciences
- Statistically Significant Improvement in Chorea Associated with Huntington''s Disease Seen as Early as Week 2 - Chorea Improvement Supported by Statistically Significant Clinical Global Impression of Change (CGI-C) Response Status and Patient Global Impression of Change (PGI-C) Response Status
Neurocrine Biosciences, Inc. 2022 Q4 - Results - Earnings Call Presentation (NASDAQ:NBIX) 2023/02/07 18:16:18 Seeking Alpha
The following slide deck was published by Neurocrine Biosciences, Inc.
Congenital Adrenal Hyperplasia Market to Witness Upsurge in Growth During the Forecast Period (2022-2032), Examines DelveInsight | Key Companies - Spruce Biosciences, Neurocrine Biosciences, BridgeBio Pharma 2023/02/07 10:24:51 OpenPR
The Congenital Adrenal Hyperplasia market is expected to surge due to the disease''s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Congenital Adrenal Hyperplasia pipeline products will significantly revolutionize the Congenital Adrenal Hyperplasia market dynamics.
Neurocrine Biosciences, Inc. (NBIX) Q4 2022 Earnings Call Transcript 2023/02/06 19:52:06 Seeking Alpha
Start Time: 08:00 January 1, 0000 9:02 AM ETNeurocrine Biosciences, Inc.
Neurocrine Bio Tops Fourth-Quarter Views As Profit Skyrockets 2023/02/06 13:56:51 Investor''s Business Daily
Neurocrine Biosciences reported strong fourth-quarter profit growth on Monday and beat fourth-quarter estimates. But NBIX stock was flat.
Earnings Scheduled For February 6, 2023 2023/02/06 12:58:55 Benzinga
Companies Reporting Before The Bell • Cummins (NYSE: CMI ) is projected to report quarterly earnings at $4.56 per share on revenue of $7.21 billion. • ON Semiconductor (NASDAQ: ON ) is expected to report quarterly earnings at $1.27 per share on revenue of $2.08 billion. • Neurocrine Biosciences (NASDAQ: NBIX ) is likely to report quarterly earnings at $1.14 per share on revenue of $409.09 million. • Affiliated Managers Group (NYSE: AMG ) is projected to report quarterly earnings at $7.06 per share on revenue of $589.28 million. • Tyson Foods (NYSE: TSN ) is expected to report quarterly earnings at $1.36 per share on revenue of $13.52 billion. • Energizer Hldgs (NYSE: ENR ) is estimated to report quarterly earnings at $0.76 per share on revenue of $785.86 million. • IDEXX Laboratories (NASDAQ: IDXX ) is projected to report quarterly earnings at $1.94 per share on revenue of $820.91 million. • CNA Financial (NYSE: CNA ) is estimated to report quarterly earnings at $0.97 per share on revenue of $2.28 billion. • NAPCO Security Techs (NASDAQ: NSSC ) is expected to report quarterly earnings at $0.14 per share on revenue of $39.14 million. • Daseke (NASDAQ: DSKE ) is estimated to report quarterly earnings at $0.06 per share on revenue of $397.07 million. • Loews (NYSE: L ) is projected to report earnings for its fourth quarter. • Alico (NASDAQ: ALCO ) is likely to report quarterly loss at $0.31 per share on revenue of $8.10 million. • Graham (NYSE: GHM ) is estimated to report quarterly loss at $0.10 per share on revenue of $30.00 million. • Timken (NYSE: TKR ) is expected to report quarterly earnings at $1.09 per share on revenue of $1.09 billion. • ORIX (NYSE: IX ) is estimated to report earnings for its third quarter. • Mesa Laboratories (NASDAQ: MLAB ) is likely to report quarterly earnings at $0.14 per share on revenue of $57.74 million.
Neurocrine Biosciences Dumpster-Dives To Accelerate Its International Business Development 2022/08/31 15:50:41 Seeking Alpha
Neurocrine is acquiring beaten-down Diurnal Group for $57M to accelerate its ex-U.S. business development. Find out what this means for investors in NBIX stock.
NBIX stock on watch after deal to acquire Diurnal (NASDAQ:NBIX) 2022/08/30 11:32:08 Seeking Alpha
The shares of U.K.-based biotech Diurnal rose in London in the morning hours Tuesday after the company announced a deal to be acquired by San Diego, California-based Neurocrine…
Neurocrine Is Seeing A Welcome Pick Up In Ingrezza, But Pipeline Catalysts Are Thin (NBIX) 2022/08/08 16:36:19 Seeking Alpha
Neurocrine saw a meaningful improvement in Ingrezza sales, with revenue growing 32% and beating sell-side expectations by 8%.
Neurocrine stock rises as Q2 revenue soars 31% Y/Y, raises sales outlook for Ingrezza 2022/08/05 16:45:36 Seeking Alpha
Neurocrine Biosciences (NBIX) stock rose ~8% on Aug
Neurocrine Biosciences Shares Jump After Raising Ingrezza Sales Guidance 2022/08/05 15:33:40 Benzinga
Tucked in its Q2 earning release , Neurocrine Biosciences Inc (NASDAQ: NBIX ) said that in August, the Phase 2a study of NBI-827104 in essential tremor did not meet specified endpoints. Based on the totality of data from the Phase 2a study, at this time, the company will not proceed further with the clinical development of NBI-827104 in essential tremors. The Full story available on Benzinga.com